WuXi Biologics Expands Manufacturing Capacity in Germany
Company is expanding its manufacturing capacity for drug substance and drug product at its sites in Leverkusen and Wuppertal, Germany.
WuXi Biologics, a contract research, development, and manufacturing organization (CRDMO), will increase its manufacturing capacity at two of its sites in Germany. The expansion will include drug substance and drug product manufacturing capacity.
At Chempark Leverkusen, Germany, the company’s sterile filling and freeze-drying plant for drug products, WuXi Biologics will add a second variable filling line. The Leverkusen site currently has an annual capacity of approximately 10 million doses. At Wuppertal, Germany, the company’s drug substance facility, WuXi Bio intends to double total capacity from 12,000 L to 24,000 L on nearly 323,000 square feet.
The two site expansions is expected to enhance WuXi Bio’s clinical and commercial manufacturing capacities in Europe, and will strengthen its global dual-sourcing network strategy. Doing so—the CRDMO says—will ensure that materials can be sourced and products manufactured at multiple sites within the company’s network
."WuXi Biologics’ increased capacity in Germany is intended to meet the growing needs of our global customers, especially those in Europe, thereby aligning us with the company's global strategy to work in close proximity to our clients. … The expansion of the two facilities is a clear commitment to Germany and Europe as high-tech locations and WuXi Biologics’ long-term growth strategy," notes Benjamin Minow, managing director of WuXi Biologics Germany.
